NTT and Tohoku University Pioneer Quantum Leap with Single-Photon Coherent Ising Machines NTT Research and Tohoku University have jointly achieved a significant scientific milestone, pushing the boundaries of quantum computing by developing a highly energy-efficient and powerful form of Coherent…
Blue Lake and CyanVac Publish Phase 1 Data for Intranasal COVID-19 Vaccine Candidate Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company, and its affiliate CyanVac LLC have announced the publication of the full Phase 1 clinical study data for…
Allurion Submits Final PMA Module to FDA Following Strong AUDACITY Study Results Allurion Technologies, Inc., a global leader in innovative, non-surgical weight loss solutions, announced it has officially submitted the final module of its Pre-Market Approval (PMA) application to the…
Miach Orthopaedics Completes Enrollment in BEAR MOON ACL Study Miach Orthopaedics, Inc., a medical device company revolutionizing anterior cruciate ligament (ACL) treatment, announced that patient enrollment is now complete for its pivotal BEAR MOON study. This major clinical trial compares…
Lab-on-a-Chip and Microfluidics World Congress 2025 Set to Explore Next-Gen Diagnostics, 3D Bioprinting, and Commercialization The 18th Annual Lab-on-a-Chip & Microfluidics World Congress 2025, now officially included in the ResearchAndMarkets.com conference offering, is poised to once again bring together innovators,…
ICON Recognized Globally for Clinical Research Leadership, Innovation, and Sustainability in 2025 ICON plc , a global leader in healthcare intelligence and clinical research, has earned multiple prestigious accolades in the first half of 2025, reinforcing its reputation as a…
FDA Approves KalVista’s EKTERLY® as First Oral On-Demand Treatment for Hereditary Angioedema KalVista Pharmaceuticals, Inc. has announced a landmark development in the treatment of hereditary angioedema (HAE): the U.S. Food and Drug Administration (FDA) has officially approved EKTERLY® (sebetralstat), the…
Lubrizol’s Apinovex™ Polymer Honored with Prestigious Pharma Excipients Award at CPhI China 2025 Lubrizol Life Science Health’s Apinovex™ polymer has been awarded a prestigious Celebration Award in the Pharma Excipients Award category at CPhI China 2025, held in Shanghai from…
Secures $2.15M NIH Grant to Advance AI-Driven Platform for CNS Drug Safety Prediction Quiver Bioscience, a discovery-stage biotechnology company focused on the treatment of serious central nervous system (CNS) disorders and chronic pain, has received a prestigious Phase II Small…
Market Outlook: Explosive Growth to 2030 The global oligonucleotide synthesis market is forecast to grow at a compound annual growth rate (CAGR) of 18.6%, reaching an estimated USD 24.7 billion by 2030, up from USD 10.5 billion in 2025. This dramatic increase reflects surging…
Vertex Secures EU Approval for ALYFTREK®, a New Once-Daily Treatment for Cystic Fibrosis Vertex Pharmaceuticals announced that the European Commission (EC) has approved ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who…
Sensorion Reports Promising Early Data from Phase 1/2 Audiogene Gene Therapy Trial Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing innovative therapies for hearing loss, has announced encouraging preliminary results from the first cohort of its Phase…